1362. A Novel Intravesical Antimicrobial for CAUTIs
Session: Poster Abstract Session: Novel Agents
Friday, October 5, 2018
Room: S Poster Hall
Background: As many as 1.5 million people reside in long-term care facilities in the United States. Nearly all of these patients will develop catheter-associated urinary tract infections (CAUTIs) within a month of catheterization. These infections collectively cost the healthcare system billions of dollars each year. In addition, the emergence of multi-drug resistant ESKAPE (Enterobacter species, Staphylococcus aureus, Klebsiella species, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterococcus species) pathogens affects the severity of infections, increasing both morbidity and mortality. Our research group is exploring a novel, dual-acting, antimicrobial, glycerol monolaurate (GML)-containing gel to prevent and treat CAUTIs.

Methods: Pieces (7 mm in length) of RenaSil Silicone Tubing were placed in the bladders of BALB/c female mice (n=5/group). Approximately 1 x 108 colony-forming units/mL ESKAPE pathogens (50 µl) were inoculated into the bladder, and animals were returned to cages for 18 h. One hundred microliters of 2.5% GML Gel (50:50 mix of saline and human-approved glycols) or phosphate-buffered saline (placebo) was administered into the bladders. After 2 h, animals were euthanized and colony-forming units in bladders and on catheters were determined, and histological analysis of bladders was performed.

Results: GML Gel was bactericidal against ESKAPE pathogens at 2 h post-treatment. Subsequent histological analysis of bladders from infected and noninfected mice showed that GML Gel was not toxic to bladder tissue.

Conclusion: Our results in this murine catheter infection model indicate that the newly formulated GML Gel may be useful in prevention and treatment of CAUTIs.

Marnie Peterson, PharmD, PhD1, Samuel Kilgore, BS2 and Patrick Schlievert, PhD2, (1)Hennepin Life Sciences, Plymouth, MN, (2)University of Iowa, Iowa City, IA


M. Peterson, Hennepin Life Sciences: Board Member , Consulting fee .

S. Kilgore, Hennepin Life Sciences: Employee , Salary .

P. Schlievert, Hennepin Life Sciences: Board Member , Consulting fee .

See more of: Novel Agents
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.